Lakefront Biotherapeutics (LKFT) Other Operating Expenses (2015 - 2026)

Lakefront Biotherapeutics (LKFT) has reported Other Operating Expenses for 11 consecutive years, with $1.3 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Other Operating Expenses fell 81.73% year-over-year to $1.3 million; the TTM figure through Mar 2026 stood at -$923.3 million (down 1197.42% YoY), while the FY2025 annual figure was $62.3 million, up 42.92% from the prior year.
• Other Operating Expenses improved to $1.3 million in Q1 2026 per LKFT's latest filing, from -$1.4 billion in the prior quarter.
• Across five years, Other Operating Expenses topped out at $432.6 million in Q3 2025 and bottomed at -$1.4 billion in Q4 2025.
• Historically, Other Operating Expenses has averaged -$43.6 million across 5 years, with a median of $10.2 million in 2024.
• On a YoY basis, Other Operating Expenses climbed as much as 1490.04% in 2025 and fell as far as 2369.31% in 2025.
• Lakefront Biotherapeutics' Other Operating Expenses stood at $6.8 million in 2022, then soared by 106.07% to $14.0 million in 2023, then surged by 329.36% to $60.1 million in 2024, then plunged by 2369.31% to -$1.4 billion in 2025, then surged by 100.09% to $1.3 million in 2026.
• Business Quant data shows LKFT's Other Operating Expenses at $1.3 million in Q1 2026, -$1.4 billion in Q4 2025, and $432.6 million in Q3 2025.